Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer : A Subgroup Analysis of TITAN
BACKGROUND AND OBJECTIVE: A post hoc analysis of TITAN evaluated the clinical benefit of apalutamide plus androgen-deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (mHSPC) with high disease burden. METHODS: Patients were assessed in subgroups of those with four to fewer than ten, ten to <20, or ≥20 bone metastases; with lung but not liver metastases; and w
